Your Location: Set Location
Your location:
See services nearest you.
Menu
Search
Essentia Health Menu
Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
Back to Results
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.
https://www.clinicaltrials.gov/ct2/show/NCT02502266
Contact Phone: 218-786-3308 | 1-844-681-7944
Email: cancertrials@essentiahealth.org
Locations: Essentia Health Cancer Centers
Disclosures:
None
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.
